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Background: Idiopathic pulmonary ﬁbrosis (IPF) may be complicated by episodes of acute exacerbation.
This study quantiﬁed the association between occurrence of suspected acute exacerbations of IPF (AEx-
IPF) in the 6 months post-IPF diagnosis with clinical outcomes and IPF-related healthcare resource
utilization (HRU).
Methods: U.S. pulmonologists participated in a retrospective chart review of IPF patients. Patient eligi-
bility criteria included: 1) 40 years of age and a conﬁrmed date of ﬁrst IPF diagnosis with HRCT and/or
lung biopsy between January 2011eJune 2013; 2) 2 separate FVC results recorded around ﬁrst diagnosis
and 6 months post-diagnosis. Patients with a suspected AEx-IPF within 6 months post-diagnosis were
categorized as “early AEx-IPF.” Subsequent clinical outcomes and IPF-related HRU were assessed from 6
months post-diagnosis until the latest physician contact date.
Results: The sample included 490 IPF patients from 168 pulmonologists; 72 (15%) patients had a sus-
pected early AEx-IPF. At IPF diagnosis, the mean (SD) age was 61 (11) years, 68% were male, and the mean
FVC percent predicted was 60% (26%). Compared to patients without a suspected early AEx-IPF, patients
with an early AEx-IPF had higher mortality risk (HR ¼ 2.87, p < 0.001) and higher rates of subsequent
suspected AEx-IPF (IRR ¼ 3.87, p < 0.001), outpatient visits (IRR ¼ 1.46, p < 0.001), ER visits (IRR ¼ 4.39,
p < 0.001), hospitalizations (IRR ¼ 7.96, p < 0.001), and ICU stays (IRR ¼ 9.74, p < 0.001).
Conclusions: Using a large sample of IPF patients from varied practice settings, we found a strong rela-
tionship between suspected early AEx-IPF and worse subsequent clinical outcomes and increased IPF-
related HRU. This relationship was particularly pronounced for acute resource use.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Idiopathic pulmonary ﬁbrosis (IPF) is a rare, chronic, and
debilitating pulmonary disease of unknown etiology characterized
by the progressive loss of lung function. The clinical course of IPF is
highly variable: patients with IPF may remain stable, progressim.com (Y.F. Yu), Dendy.
Bill.Reichmann@gmail.com
. Wu), Steven.Nathan@inova.
Ltd. This is an open access article usteadily over time, progress rapidly, or experience episodes of acute
deterioration [1]. Some of these acute episodes may be due to acute
exacerbations of IPF (AEx-IPF), but this diagnosis is contingent on
ruling out other causes such as progression of disease, pneumonia,
heart failure or thromboembolic events [1e4].
The incidence of AEx-IPF varies widely across studies, mainly
due to differences in the deﬁnition of AEx-IPF, characteristics of the
study cohort, and study design [3e5]. Recent guidelines suggest
that the incidence of AEx-IPF ranges between 5% and 10% annually
[1]. AEx-IPF may occur at any time during the course of IPF and in
some cases can be the reason for seeking care [2,4]. Prior studies
have shown that diminished lung function, higher BMI, or priornder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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[2,6,7]. AEx-IPF is associated with signiﬁcant morbidity and mor-
tality. When AEx-IPF leads to hospitalization, the rate of mortality is
usually high, ranging between 71% and 92% [6e10]. Median overall
survival after an AEx-IPF has been reported to range between 22
days and 4.2 months, further highlighting the signiﬁcant impact on
mortality [6,7,10]. To date, there are limited data on AEx-IPF in real-
world settings and its association with clinical outcomes and IPF-
related healthcare resource utilization (HRU). Data on the impact
of early AEx-IPF on subsequent outcomes could be useful for the
management of IPF.
This study aimed to address the evidence gap using a large
sample of IPF patients whose medical record data were drawn by
treating pulmonologists from a nationwide panel, allowing for a
more “real-world” study population inclusive of different treat-
ment settings. The objective of this study was to quantify the as-
sociation of suspected early AEx-IPF with clinical outcomes and
IPF-related HRU in patients newly diagnosed with IPF.
2. Methods
2.1. Sample
A retrospective chart review study was conducted among pul-
monologists from a nationally representative panel using an online
case report form. The panel comprised over 1000 pulmonologists
working in both academic and non-academic institutions, and
covering all regions of the U.S. The pulmonologist panel was
demographically similar to those on the American Medical Asso-
ciation master list [11].
Pulmonologists on the panel were invited via e-mail to partic-
ipate. Thosewho accepted the invitation completed a questionnaire
to assess their eligibility. Pulmonologists were eligible to partici-
pate if they had complete access to their patients' IPF-related
medical records (inpatient and outpatient). Eligible physicians
were requested to randomly select IPF patients who met the
following inclusion criteria for this study: 1) 40 years or older with
a conﬁrmed date of ﬁrst IPF diagnosis with high-resolution
computed tomography (HRCT) and/or lung biopsy between
January 1, 2011 and June 30, 2013; and 2) pulmonary function tests
measured using forced vital capacity (FVC) that were recorded at or
around ﬁrst IPF diagnosis (±1 month) and at or around 6 months
(±3months) following diagnosis. The second criterion ensured that
all patients would have FVC measurements around their initial IPF
diagnosis and during the follow-up period, which was used for the
assessment of FVC change [12,13]. Data were collected from the
date of initial IPF diagnosis until last follow-up. The last follow-up
date was deﬁned as either: 1) the last contact the pulmonologist
had with the patient for those who were alive as of chart abstrac-
tion; or 2) the date of death for the deceased.
Pulmonologists were compensated for their participation and
remained anonymous to the study sponsor and vice versa. The
electronic case report form was approved by the New England
Institutional Review Board, which granted exemption from a full
review because this non-interventional study collected retrospec-
tive, de-identiﬁed data. Patient consent forms were not required,
and the chart abstraction form did not request any information that
could be linked to a patient's identity, such as name, date of birth,
date of death, or social security number.
2.2. Explanatory and outcome variables
The main independent variable of interest was suspected AEx-
IPF in the ﬁrst 6 months after initial IPF diagnosis, termed here as
“early AEx-IPF.” Participating pulmonologists provided informationon IPF-related HRU in the outpatient, emergency room (ER), and
hospital settings. Suspected AEx was deﬁned by asking partici-
pating pulmonologists if a particular outpatient visit, ER visit, or
hospitalization was related to an IPF AEx. IPF patients with a sus-
pected early AEx-IPF in any setting were categorized into an “early
AEx-IPF” group, while those without a suspected early AEx-IPF
during the same period were categorized into a “without early
AEx-IPF” group.
Demographics, comorbidities, symptoms, exposure history (i.e.,
smoking and environmental exposures such as asbestos, farming/
agriculture, hairdressing, metal dust, stone cutting/polishing, and
coal mining), and lung function data were collected as of the initial
IPF diagnosis. Lung function measures included FVC, forced expi-
ratory volume after 1 min (FEV1), FEV1/FVC ratio, and the single
breath diffusing capacity for the lung for carbon monoxide (DLCO).
Clinical characteristics and IPF-related HRU were summarized
for the ﬁrst 6 months after initial IPF diagnosis and from 6 months
after initial IPF diagnosis until the end of follow-up. These vari-
ables included IPF progression and number of IPF-related outpa-
tient visits, ER visits, and hospitalizations. IPF progression was
based on physician reporting of emergence of any of the following
since the previous visit: progressive dyspnea, increased cough,
sustained decrease from baseline in absolute FVC and DLCO, pro-
gression of ﬁbrosis from baseline on HRCT, AEx-IPF, respiratory
failure, new need for supplemental oxygen, or increase in oxygen
requirements.
Subsequent clinical outcomes were assessed from 6 months
after initial IPF diagnosis until the end of follow-up. These outcome
measures included subsequent suspected AEx-IPF, IPF progression,
all-cause mortality, mortality due to IPF, and mortality due to an
AEx-IPF. AEx-IPF events that occurred within 28 days of one
another were considered to be part of the same AEx-IPF event. IPF-
related HRU outcomes were collected in the outpatient, ER, and
hospital settings and included the timing and number of routine
outpatient visits, unscheduled outpatient or urgent care visits, ER
visits, hospitalizations, hospital days, intensive care unit (ICU) stays,
and days in the ICU.
2.3. Statistical analysis
Summary statistics for characteristics of the treating physician
and their practice were calculated. Patient characteristics at the
time of diagnosis were compared between patients with and
without suspected early AEx-IPF, using Chi-square tests for binary
variables and t-tests for continuous variables.
The incidence rate (IR) or risk of clinical and HRU outcomes was
assessed using unadjusted regression analysis with suspected early
AEx-IPF as the sole independent variable. Estimates were presented
as 6-month IRs or risks for outcomes assessed in the ﬁrst 6 months
post-IPF diagnosis and as 12-month IRs or risks for outcomes
assessed from 6 months post-IPF diagnosis until end of follow-up.
Negative binomial regressions were used to estimate the inci-
dence rate ratios (IRRs) and their 95% conﬁdence interval (CI) for
count variable outcomes. Logistic regressions were used to esti-
mate the odds ratios (OR) and their 95% CI for binary variable
outcomes (except mortality). For both negative binomial and lo-
gistic models, patient-speciﬁc offset termswere used to account for
varying follow-up time. The risk of death by 12 months was esti-
mated by KaplaneMeier analysis, and an unadjusted Cox propor-
tional hazards regression was used to estimate the hazard ratio
(HR) and its 95% CI.
Additionally, multivariable Cox proportional hazards regression
was performed to assess factors associated with all-causemortality,
hospitalizations, and future AEx-IPF. The HR and 95% CI for each risk
factor were estimated.
Table 1
Baseline patient characteristics at initial IPF diagnosis by suspected early AEx-IPF.
Early AEx-IPFa
(N ¼ 72)
Without Early AEx-IPFa
(N ¼ 418)
P-value
Male, N (%) 46 (63.9%) 289 (69.1%) 0.355
Age (years), mean (SD) 59.0 (10.8) 61.4 (10.7) 0.106
BMI, mean (SD) 26.6 (5.3) 26.6 (4.6) 0.981
Race, N (%)b
White 49 (68.1%) 320 (76.6%) 0.146
Black or African American 13 (18.1%) 56 (13.4%) 0.329
Hispanic, Latino, or Spanish Origin 8 (11.1%) 36 (8.6%) 0.520
Asian 1 (1.4%) 8 (1.9%) 0.754
Other 1 (1.4%) 1 (0.2%) e
Insurance type, N (%)b
Commercial/private insurance 35 (48.6%) 203 (48.6%) 0.995
Medicare 25 (34.7%) 189 (45.2%) 0.111
Medicaid 14 (19.4%) 41 (9.8%) 0.036*
Military insurance (VA or active military) 3 (4.2%) 11 (2.6%) 0.457
Other 0 (0.0%) 1 (0.2%) e
No insurance 2 (2.8%) 8 (1.9%) 0.640
Smoking status at diagnosis 0.034*
Never smoked 18 (25.0%) 172 (41.1%)
Former smoker 42 (58.3%) 201 (48.1%)
Current smoker 11 (15.3%) 37 (8.9%)
Unknown/not sure 1 (1.4%) 8 (1.9%)
Exposure to activities/environmental agentsb
Asbestos 5 (6.9%) 19 (4.5%) 0.359
Farming/agriculture 14 (19.4%) 47 (11.2%) 0.029*
Hairdressing 5 (6.9%) 15 (3.6%) 0.150
Metal dust 8 (11.1%) 22 (5.3%) 0.071
Stone cutting/polishing 6 (8.3%) 7 (1.7%) <0.001*
Coal mining 1 (1.4%) 7 (1.7%) 0.862
Other 2 (2.8%) 6 (1.4%) 0.405
None 42 (58.3%) 310 (74.2%) 0.010*
Family history of pulmonary ﬁbrosis 3 (4.2%) 24 (5.7%) 0.662
Total follow-up (days), mean (SD) 546.7 (274.9) 588.7 (288.4) 0.300
Lung function measures at IPF diagnosis, mean (SD)
FVC (liters) 2.2 (1.1) 2.5 (1.0) 0.055
FVC% 55.8% (28.9%) 61.2% (25.6%) 0.165
FEV1 (liters) 1.6 (0.8) 1.9 (0.8) 0.007*
FEV1/FVC 76.7% (16.2%) 80.5% (11.6%) 0.093
DLCO, % predicted 43.9% (16.4%) 52.6% (15.1%) <0.001*
FVC % predicted decline during the 6 months post-IPF diagnosis, n (%) 0.185
<5% 31 (43.1%) 219 (52.4%)
5% and <10% 13 (18.1%) 85 (20.3%)
10% 28 (38.9%) 114 (27.3%)
Notes:
*P < 0.05
a Based on development of suspected early AEx-IPF as determined by pulmonologists.
b Physicians were allowed to select multiple values for insurance type and environmental agents, so counts and percentages may not sum to the total N or 100%.
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with clustering to account for correlation of multiple patient charts
contributed by the same pulmonologist. P-values that were less
than 0.05 were considered statistically signiﬁcant. All statistical
analyses were performed using SAS version 9.3.
3. Results
3.1. Physician characteristics
A total of 168 pulmonologists participated in this study, of
whom 69 (41.1%) practiced in an academic setting. The practices
were distributed across the Northeast (36.3%), South (25.0%),
Midwest (20.8%), and West (17.9%) of the U.S. The mean (SD)
number of years in practice for the pulmonologists was 15.0 (6.4),
with each on average contributing data abstracted from 3 patient
charts.
3.2. Patient characteristics
Of the 490 IPF patients who were included in this study, 72(14.7%) had a suspected early AEx-IPF, and 418 (85.3%) did not. The
mean (SD) follow-up time for the entire samplewas 583 (287) days.
The majority of IPF patients were male (68.4%), and the mean (SD)
age was 61.1 (10.8) years. At the initial IPF diagnosis date, the mean
(SD) FVC of the sample was 2.5 (1.0) liters, and the mean FVC
percent predicted (FVC%) was 60.4% (26.1%); DLCO percent pre-
dicted was 51.3% (15.5%). Patients with a suspected early AEx-IPF
were more likely to have Medicaid insurance, smoke, and experi-
ence environmental exposures compared to patients without a
suspected early AEx-IPF. Patients with a suspected early AEx-IPF
were also more likely to have lower FEV1 and DLCO percent pre-
dicted at initial IPF diagnosis compared to those without a sus-
pected early AEx-IPF (Table 1). Gastroesophageal reﬂux disease at
initial IPF diagnosis was the most commonly reported comorbidity
across the full sample (31.2%). The proportion of patients with
speciﬁc IPF-related comorbidities at diagnosis was similar between
patients with and without suspected early AEx-IPF (Fig. 1). With
respect to symptoms at IPF diagnosis, patients with a suspected
early AEx-IPF were more likely to experience fatigue/malaise
(58.3% vs. 45.5%) and have a rapid, shallow breathing pattern (18.1%
vs. 8.9%) (Fig. 2).
Fig. 1. IPF-related comorbidities at initial IPF diagnosis.
Fig. 2. IPF-related symptoms at IPF diagnosis.
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ﬁrst 6 months
Patients with suspected early AEx-IPF had a higher risk of pro-
gression and higher rates of IPF-related HRU in the ﬁrst 6 months
post-IPF diagnosis compared to those patients without an early
AEx-IPF (Table 2).3.4. Descriptive analysis of clinical outcomes and IPF-related HRU
after the ﬁrst 6 months
Patients with suspected early AEx-IPF were associated with
signiﬁcantly worse clinical outcomes compared to those without a
suspected early AEx-IPF. This included higher risk of subsequentsuspected AEx-IPF (OR ¼ 5.04), rate of subsequent suspected AEx-
IPF (IRR ¼ 3.87), and mortality (all-cause (HR ¼ 2.87), IPF-related
(HR ¼ 3.15), and AEx-IPF-related (HR ¼ 3.37)). Patients with sus-
pected early AEx-IPF were also associated with signiﬁcantly higher
IPF-related HRU for all settings compared to those without a sus-
pected early AEx-IPF (Table 3).3.5. Multivariable analysis
Results of the multivariable analysis showed that patients with
suspected early AEx-IPF were associated with signiﬁcantly shorter
overall survival (HR ¼ 2.83), time to hospitalization (HR ¼ 1.90),
and time to subsequent AEx (HR ¼ 2.96) compared to patients
without suspected early AEx-IPF, adjusting for confounding factors.
Table 2
Clinical characteristics and healthcare resource utilization in the ﬁrst 6 months post-initial IPF diagnosis by suspected early AEx-IPF.
Early AEx-IPFa
(N ¼ 72)
Without Early AEx-IPFa
(N ¼ 418)
P-value
6-Month Risk
Any evidence of progression 60.5% 28.8% <0.001*
6-Month IR per Patient
Number of IPF-related outpatient visits 2.46 1.74 <0.001*
Unscheduled and/or for urgent care 0.72 0.07 <0.001*
Number of IPF-related ER visits 0.57 0.08 <0.001*
Number of IPF-related hospitalizations 0.30 0.01 <0.001*
Number of hospital days 1.78 0.10 <0.001*
Number of ICU stays 0.14 0.00 <0.001*
Number of ICU days 0.45 0.03 0.003*
Notes: IR: Incidence rate.
*P < 0.05.
a Based on development of suspected early AEx-IPF in the ﬁrst 6 months as determined by pulmonologists.
Table 3
Clinical outcomes and healthcare resource utilization assessed from 6 months post-initial IPF diagnosis until last follow-up by suspected early AEx-IPF.
Early AEx-IPFa
[A]
(N ¼ 72)
Without Early AEx-IPFa
[B]
(N ¼ 418)
Relative effect measure
[A] vs. [B]
(95% CI)
P-value
12-Month Risk OR
Any suspected AEx-IPF 62.0% 24.5% 5.04 (2.61e9.72) <0.001*
Any evidence of progression 79.8% 71.2% 1.59 (0.77e3.32) 0.212
Risk by 12 Months HR
Mortalityb
Death due to any cause 27.0% 11.5% 2.87 (1.68e4.89) <0.001*
Death due to IPF 24.6% 9.4% 3.15 (1.72e5.77) <0.001*
Death due to AEx 15.5% 6.8% 3.37 (1.65e6.90) 0.001*
12-Month IR per Patient IRR
Number of AEx-IPF 1.07 0.28 3.87 (2.51e5.97) <0.001*
Number of IPF-related outpatient visits 3.24 2.22 1.46 (1.17e1.82) <0.001*
Unscheduled and/or for urgent care 0.85 0.18 4.62 (2.74e7.81) <0.001*
Number of IPF-related ER visits 1.25 0.28 4.39 (2.21e8.74) <0.001*
Number of IPF-related hospitalizations 1.24 0.16 7.96 (3.34e18.97) <0.001*
Number of hospital days 6.18 1.85 3.34 (1.35e8.30) 0.009*
Number of ICU stays 0.48 0.05 9.74 (3.80e24.97) <0.001*
Number of ICU days 1.84 0.39 4.74 (1.66e13.55) 0.004*
Notes: IR: Incidence rate; IRR: Incidence rate ratio; OR: Odds ratio.
*P < 0.05.
a Based on development of suspected early AEx-IPF as determined by pulmonologists.
b KaplaneMeier survival analysis was used to estimate the risk of death by 12 months.
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initial IPF diagnosis and pulmonary hypertension were associated
with signiﬁcantly shorter time to each endpoint (Table 4).
4. Discussion
In this retrospective chart review, IPF patients with a suspected
early AEx-IPF after diagnosis were associated with increased rates
of mortality, subsequent AEx-IPF, and IPF-related HRU. While these
results are not unexpected on their own, this study quantiﬁed their
relationship and found large and noteworthy magnitudes. Patients
with an early AEx-IPF had a 3.9-fold increase in the rate of subse-
quent suspected AEx-IPF and a 2.9-fold increase in the risk of death.
IPF-related HRUwas also substantially impacted as patients with an
early suspected AEx-IPF had a 4.4-fold increase in the rate of ER
visits and an 8.0-fold increase in the rate of hospitalizations.
To our knowledge, this is the ﬁrst study to compare clinical
outcomes and IPF-related HRU between patients with and without
an early suspected AEx-IPF. While it is not surprising that we
observed signiﬁcant differences between patients with and
without an early suspected AEx-IPF, this study adds to the literatureby quantifying the clinical and HRU burden of these events in a
broad group of patients across a wide geographic and practice
setting spectrum. Consistent with ﬁndings in previous studies on
AEx-IPF, we demonstrate that early suspected AEx-IPF has a sig-
niﬁcant impact onmortality and hospitalization. Indeed, our hazard
ratio for death from the multivariable analysis (HR ¼ 2.9) is
remarkably similar to that from a prior study that demonstrated a
2.6-fold increase in the risk of death for patients with an AEx-IPF
compared to those without [7].
Our study has several strengths. These include having a large
sample size of patients from community clinics and academic
centers across the U.S., making the sample reﬂective of real-world
IPF practice. Additionally, the patient medical charts provided
more comprehensive patient details and clinical granularity, which
are not commonly found in administrative claims data. IPF diag-
nosis was conﬁrmed by HRCT or biopsy as reported by the pul-
monologist and is likely to be more accurate than a diagnosis/
procedure code-based IPF patient identiﬁcation algorithm.
The main limitation of our study is that AEx-IPF was based on
the pulmonologist report in the outpatient, ER, and hospital set-
tings, which likely does not reﬂect the deﬁnition proposed by the
Table 4
Multivariable Cox proportional hazards regression for risk of mortality, hospitalization, and acute exacerbation during the subsequent perioda.
Characteristic (N ¼ 490) Hazard ratio (95% conﬁdence interval)b
Overall survival Hospitalization Subsequent AEx
Early AEx-IPF (vs. without early AEx-IPF) 2.83 (1.60e5.00)* 1.90 (1.08e3.35)* 2.96 (1.84e4.74)*
FVC % predicted decline (during the 6 months post-IPF diagnosis)
5 and < 10% decline vs. <5% decline 2.40 (1.06e5.44)* 2.35 (0.98e5.62) 2.11 (1.18e3.76)*
10% decline vs. <5% decline 4.62 (2.08e10.26)* 3.58 (1.70e7.51)* 2.92 (1.70e5.00)*
Age group (years)
50e64 vs. 40e49 1.11 (0.53e2.32) 1.74 (0.77e3.94) 0.74 (0.45e1.21)
65e74 vs. 40e49 1.51 (0.70e3.27) 1.79 (0.78e4.09) 0.98 (0.57e1.70)
75 vs. 40e49 2.06 (0.78e5.46) 1.95 (0.68e5.55) 0.94 (0.49e1.78)
Male 0.78 (0.44e1.40) 1.13 (0.66e1.93) 0.87 (0.57e1.33)
White (vs. non-white) 0.72 (0.40e1.27) 0.54 (0.34e0.85)* 0.63 (0.45e0.89)*
BMI
25e29 vs. <25 0.60 (0.33e1.11) 0.64 (0.35e1.16) 0.85 (0.54e1.36)
30 vs. <25 0.39 (0.18e0.87)* 1.04 (0.55e1.97) 0.77 (0.46e1.29)
Comorbidities
Cardiac disorder 1.52 (0.84e2.74) 1.87 (1.03e3.42)* 1.54 (1.00e2.38)
Pulmonary hypertension 2.64 (1.37e5.10)* 2.36 (1.31e4.24)* 1.72 (1.06e2.79)*
Emphysema 1.63 (0.69e3.86) 1.43 (0.55e3.68) 2.02 (1.09e3.77)*
Gastroesophageal reﬂux disease 1.08 (0.59e1.97) 1.08 (0.67e1.76) 1.03 (0.70e1.51)
History of smoking (vs. no history of smoking) 1.16 (0.63e2.11) 0.96 (0.58e1.59) 0.94 (0.64e1.38)
Medications used in the ﬁrst six months
Prednisone and Azathioprine vs. neither 2.61 (1.22e5.58)* 1.32 (0.62e2.81) 1.46 (0.78e2.74)
Prednisone only vs. neither 1.35 (0.63e2.91) 1.19 (0.68e2.08) 1.21 (0.79e1.85)
Azathioprine only vs. neither 1.00 (0.16e6.41) 0.66 (0.07e5.78) 0.92 (0.28e2.99)
Symptoms at initial IPF diagnosis
Dyspnea vs. no dyspnea 1.35 (0.52e3.47) 1.26 (0.36e4.46) 1.40 (0.66e2.97)
Weight loss vs. no weight loss 1.98 (0.99e3.96) 1.52 (0.78e2.96) 1.14 (0.63e2.04)
Index FVC % predicted (per 10% decline)c 1.09 (1.00e1.20) 1.15 (1.02e1.28)* 1.06 (0.98e1.15)
Practice setting (academic vs. non-academic) 1.00 (0.54e1.87) 0.88 (0.50e1.52) 1.04 (0.70e1.53)
Notes:
*P < 0.05.
a The “subsequent period”was deﬁned as the interval between the second FVC measurement and the date of last follow-up. The second FVC measurement was speciﬁed to
fall 6 months after IPF diagnosis (±3 months).
b Multivariable Cox proportional hazard regression was used to estimate the HR and 95% conﬁdence interval accounting for physician clustering using generalized esti-
mating equations and survey procedures. Time to ﬁrst acute exacerbation was deﬁned as time from the start of the subsequent period to the ﬁrst physician-deﬁned acute
exacerbation in the subsequent period (for those with an acute exacerbation event) or last follow-up (for those that were censored).
c The hazard ratio for the index FVC percent predicted is estimated for a 10% decrease in FVC percent predicted.
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to use less stringent criteria in the real world when classifying AEx-
IPF. This may occur if patients are unable to receive assessment
procedures required by the deﬁnition due to the fragility of their
health status. Consequently, the rates of suspected AEx-IPF
observed in this study may be higher than the AEx-IPF rates in
clinical trial and observational studies that use more stringent
criteria [1,7,14]. One recent retrospective study reported the 1-year
incidence of suspected AEx-IPF to be 11.6% after excluding patients
who initially presented with AEx-IPF [7]. Our study found that
14.7% of patients had a suspected early AEx-IPF, which is substan-
tially higher when comparing the timeframes. We speculate that
some cases of acute respiratory worsening may have been erro-
neously reported as an AEx-IPF by the pulmonologists participating
in this study. Although reports of suspected AEx-IPF in this study
might not conform to the strict expert committee deﬁnition, these
events still had substantial impact on downstream IFP-related HRU.
Our study provides insight into how AEx-IPF are perceived and
deﬁned in real-world clinical practice. In fact, experts recently
suggested the term “suspected acute exacerbation” [15], which
reﬂects the challenge of capturing AEx according to the stringent
criteria in real-world practice.
Further limitations are inherent to the conduct of retrospective
studies. To account for changes over time in IPF care and man-
agement, we sampled patients who were diagnosed with IPF be-
tween 2011 and 2013. Therefore, the ﬁndings may not be applicable
to patients diagnosedwith IPF prior to 2011.Whilewe required that
participating pulmonologists have complete access to their pa-
tients' medical charts, there is still the potential for incompletereporting of patient chart information from participating pulmo-
nologists. Lastly, our study design may have excluded patients on
either side of the disease severity spectrum. Speciﬁcally, requiring
that eligible patients have at least 2 FVC measures may have
excluded patients whowere not able to perform lung function tests
or those who did not survive long enough to receive a second FVC
test. This may have included patients who initially presented with a
suspected AEx-IPF. On the other end of the spectrum, there may
have been milder, more stable patients who were not seen or did
not have repeat lung function testing within the study's required
time window.
5. Conclusion
In summary, our study quantiﬁes the association of suspected
early AEx-IPF after initial IPF diagnosis on subsequent clinical
outcomes and IPF-related HRU. The ﬁndings demonstrate the
substantial burden associated with early suspected AEx-IPF on
patients and the healthcare system. Management options that
prevent AEx-IPF or reduce the risk of AEx-IPF may help to improve
health outcomes in patients with IPF.
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